Lipoteichoic acids (LTA) released by gram-positive bacteria can spontaneously bind to mammalian cell surfaces. In the present study, erythrocytes (E) sensitized with pneumococcal LTA (LTA-E) were used as a model system to determine if LTA could render host cells susceptible to damage by autologous complement.
Introduction
The membrane teichoic acids ofgram-positive bacteria are amphiphilic polysaccharides covalently linked to a terminal glycolipid moiety; hence, the name lipoteichoic acid (LTA)' (1) . Whereas nascent LTA molecules are membrane-associated, many are subsequently released by the bacterium into the surrounding environment (2) . Bacterial release of free LTA molecules has been shown to be dependent upon both time and tem-1. Abbreviations used in this paper: CoVF, cobra venom factor, C2D HS, C2-deficient human serum; C4D GPS, C4-deficient guinea pig serum; E, erythrocyte(s); GPS, guinea pig serum; GVB++, veronal-buffered saline containing gelatin, calcium, and magnesium; GVB-EDTA, veronalbuffered saline containing gelatin and EDTA; GVB-Mg-EGTA, veronalbuffered saline containing gelatin, magnesium, and EGTA; LTA, lipoteichoic acid; LTA-E, erythrocytes sensitized with pneumococcal LTA; NHS, normal human serum; NRS, normal rat serum; VBS+, veronalbuffered saline with calcium and magnesium; VBS-EDTA, veronal-buffered saline containing EDTA. perature (3) , to be independent of cell division or cell decay (3), and to be favored by bacterial exposure to certain antibiotics (3, 4) .
Certain characteristics of the LTA molecule may be of significance in the interaction ofthe bacterium and the host during infection. Through its terminal glycolipid moiety, an LTA molecule can bind to a variety of mammalian cells, including erythrocytes (5), platelets (6) , lymphocytes (7) , and buccal mucosal cells (8) . This binding has been shown to be specific, reversible, and to a single population of receptors on the cell surface (5) (6) (7) (8) . Apparently, LTA on the surface of mammalian cells retains its antigenic specificity because these cells can be agglutinated by anti-LTA antibodies (9) (10) (11) (12) . Furthermore, erythrocytes bearing LTA on their surfaces will lyse when incubated in heterologous sera via activation of either the classical or alternative complement pathways (1 1-13).
The above data suggest that the host tissue damage that occurs during the course of a bacterial infection may in part be mediated by the host's complement system directed against its own cells bearing surface LTA. The present study explored this possibility using a model system in which erythrocytes from individual animals were sensitized with pneumococcal LTA and then either exposed to autologous serum in vitro or reinfused into the animal from which they were originally obtained. The results demonstrate that LTA can render the host's cells suscep- tible to damage by its own complement system, establishing this as a possible mechanism of tissue damage in natural bacterial infections.
Methods
Buffers. Veronal-buffered saline, pH 7.4, with ionic strength 0.147 and containing 0.15 mM Ca", and I mM MgC' (VBS1), and an identical buffer containing 0.1% gelatin (GVB++), were prepared as previously described (14) . Veronal-buffered saline without Ca"+ or Mg"+ and containing 0.01 M EDTA was also prepared with 0.1% gelatin (GVB-EDTA) and without gelatin (VBS-EDTA). In some experiments, rat serum was diluted in veronal-buffered saline containing 0.1% gelatin, 3 C3 activity ( 17) . Guinea pig serum deficient in the fourth component of complement (C4) was obtained from individual animals with a genetically determined complete deficiency ofC4 (C4D GPS) (18) . For Pneumococcal LTA. Purified LTA was prepared from an unencapsulated strain of pneumococcus, R36A, as described previously (12) . Briefly, the pneumococci were grown in a chemically defined media (21) , and the organisms were harvested by centrifugation and allowed to undergo autolysis. The Aliquots of0.5 ml ofthe treated E from individual rats were injected into the dorsolateral tail veins of the animals from which they were originally obtained, and their circulatory survival was determined by the serial withdrawal of 0.1 ml of blood from the tail veins of each animal.
Each aliquot ofblood was suspended in 0.1 ml ofVBS-EDTA, the plasma was separated by centrifugation, and the relative amounts of5"Cr present in the E and plasma were determined. The percentage of predicted radioactivity was calculated based upon the dilution of the total injected counts per minute in an assumed circulating blood volume of 62 ml/kg for each animal (23) .
Organ sequestration. In some experiments, rats were killed 30 min after reinfusion of their autologous 5"Cr-labeled E and the liver, spleen, lungs, and kidneys of each animal were removed for whole organ counting.
Results
In vitro activation ofautologous complement by LTA Experiments were then conducted to determine whether LTA-E could by lysed in autologous serum via activation ofthe alternative pathway. No lysis was observed when E from an individual rat were optimally sensitized with 50 jug/ml LTA, and then incubated in 50% autologous NRS diluted in GVBMg-EDTA to block activation of the classical pathway (Table  I) . In contrast, incubation of the same cells in 50% autologous Lysis of control erythrocytes did not exceed 3%.
NRS diluted in GVB`+ resulted in 92.9% net lysis. Similarly, human E optimally sensitized with 50 ,g/ml LTA did not lyse when these cells were incubated in 50% autologous normal human serum (NHS) diluted in GVB-Mg-EGTA, whereas 100% lysis was observed when these cells were incubated in 50% autologous serum in GVB`+ (Table I) . These results were reproducible even when the time ofincubation in serum was increased from 30 to 60 min. To confirm that alternative pathway activation could occur under the above conditions, rabbit E were incubated at a concentration of 4.5 X I07 cells/ml in 50% NRS which had been diluted in GVB-Mg-EGTA. After incubation at 370C for 30 min, 100% lysis of the E was observed. The ability of LTA to sensitize autologous E for lysis via the alternative pathway was also examined using autologous E in either C2D HS or C4D GPS. As can be seen in Table I , incubation of LTA-sensitized C2D human E in 50% autologous C2D HS resulted in 72.5% lysis. Similarly, incubation of LTA-sensitized C4D guinea pig E in 50% autologous C4D GPS resulted in 30.9% lysis. The lysis ofguinea pig E presensitized with varying doses of LTA was also examined in both autologous C4D GPS and C4D GPS containing 500 U/ml of purified guinea pig C4 (Fig. 3) . While dose-dependent lysis was observed in the autologous C4D GPS, lysis of the same cells was markedly enhanced in autologous C4D GPS containing added C4. Additional experiments were performed in order to examine the apparent discrepancy between the use of EGTA and the use of either C2D HS or C4D GPS to test the ability of LTA-E to by lysed in autologous serum via the alternative pathway. Incubation of optimally sensitized rat LTA-E (50 Ag/ml of LTA) in 50% autologous NRS diluted in GVB-Mg-EGTA gave only 8.4% consumption of C3 (17) , indicating that there was no activation of the alternative pathway. In contrast, rat LTA-E incubated in 50% autologous NRS diluted in GVB++ consumed 31% of the C3. In addition, optimally sensitized human LTA-E (50 sg/ml of LTA) were not lysed in 50% rat serum which had been diluted in GVB-Mg-EGTA, indicating that the EGTA also inhibited lysis of heterologous LTA-E via the alternative pathway. Finally, experiments were performed in order to determine if treatment of the LTA-E with EGTA removed the LTA and, thereby, interfered with alternative pathway activation. When rat E were optimally sensitized with 50 sg/ml of radiolabeled LTA and then treated with GVB-Mg-EGTA, none of the radiolabeled LTA was removed.
In vivo clearance of autologous LTA-E. The following experiments were performed to determine whether complement activation could result in lysis and/or clearance of autologous LTA-E in vivo. Groups of rats were injected intravenously with either buffer-treated autologous 31Cr-labeled E or with autologous 53Cr-labeled E that had been sensitized in vitro with 50 jg/ml LTA. As can be seen in Fig. 4 , the control animals demonstrated normal survival of the autologous buffer-treated E (93.6%). In contrast, there was a rapid disappearance of the reinfused cells in the animals that received autologous LTA-E, with an average of only 2.9% remaining in the circulation after 10 min (P < 0.001). Intravascular hemolysis appeared to be responsible in large part for the disappearance of the LTA-E, as judged by the appearance of significant amounts of 5"Cr in the plasma as early as 2 min after injection (Fig. 5) .
When a similar group ofanimals was pretreated with CoVF, in order to deplete them of functional C3, the intravascular sur- Dose LTA (igl/ml) Figure 3 . Specific lysis of LTA-E from a C4-deficient guinea pig in 50% autologous C4D GPS (-) or 50% autologous C4D GPS containing 500 U/ml of purified guinea pig C4 (A). The protocol is the same as that described in Fig. 1 . There was no significant lysis of control E.
Minutes Figure 4 . Survival of 5'Cr-labeled rat E at intervals of time after infusion into autologous animals: E in normal rats (.) (n = 6), E in CoVFtreated rats (o) (n = 4), LTA-E in normal rats (A) (n = 6), and LTA-E in CoVF-treated rats (A) (n = 5). After a total volume of 0.5 ml of labeled E was injected i.v. into each recipient animal, 0. I-ml aliquots of blood were withdrawn at each time point, and the amount of 5"Cr present in the E fraction determined. Results were expressed as the mean percent predicted counts per minute (±SE) based upon the dilution of total injected counts per minute into the blood volume of each animal.
vival of autologous LTA-E was markedly improved when compared with the survival of autologous LTA-E in normal animals (P < 0.01) (Fig. 4) . The E clearance observed in this complementdeficient group was not accounted for by intravascular hemolysis, asjudged by the absence of5Cr counts from the plasma samples (Fig. 5) . Minutes Figure 5 . Presence of free 5"Cr in the plasma fractions of aliquots of blood withdrawn at intervals of time after injection of LTA-E into autologous normal rats (A) (n = 6) or CoVF-treated rats (A) (n = 5). The protocol is the same as that described in the legend to Fig. 4 Table II , 66.4% of the total injected 5"Cr activity could be recovered in the livers ofthe complement-depleted rats that had received autologous LTA-E. The liver tissue of normal rats receiving autologous LTA-E contained 26.1% of the total injected counts. This is noteworthy, because, although this group displayed evidence of intravascular hemolysis of injected cells as described earlier, only 41.5% ofthe total injected 5"Cr activity was found free in the plasma at 2 min after injection, with diminishing amounts recoverable thereafter (Fig. 5) . Only 5.8% of the total injected counts were recovered in the liver tissue removed from each of the normal and complement-depleted groups receiving unsensitized autologous E. Liver sequestration of E appeared to be irreversible, inasmuch as no increase in circulating labeled E could be detected 24 h after infusion.
Discussion
The membrane LTA of gram-positive bacteria possess certain characteristics which may be important in the interaction of the bacterium and the host during the course of an infection. They are shed by viable organisms under physiologic conditions and may then bind spontaneously to the surfaces of mammalian cells. Once attached to the cell surface, they retain their antigenic properties (9) (10) (11) (12) and can also activate the complement system in heterologous sera (12, 13) . While the binding of LTA to a variety ofmammalian cell types has been well studied (5) (6) (7) (8) and the direct cytotoxic potential ofLTA appears to be low (24), the consequences of an interaction of the cell-bound LTA with the immune system ofthe host have not been addressed. The present study examined the potential role of LTA-induced complement activation in mediating damage to autologous mammalian host cells during bacterial infections.
Previous studies have shown that E bearing surface LTA are susceptible to lysis by activation ofthe classical and/or alternative pathways of complement in heterologous sera (1 1-13) . However, there have been no studies to determine whether LTA-E are susceptible to attack by autologous complement. This is important in view of recent reports that antibody-sensitized E are relatively resistant to lysis by complement obtained from an homologous source (25, 26 The ability of LTA to sensitize E for activation of the alternative pathway under autologous conditions was examined by incubating LTA-E obtained from either a C4-deficient guinea pig or from a C2-deficient patient in their respective autologous sera. Lysis of the E was observed in each case, demonstrating that LTA can induce complement-mediated cell lysis in the absence of an intact classical pathway. However, lysis is clearly facilitated by an intact classical pathway because the lysis of LTA-E in autologous C4D GPS was significantly enhanced when C4 was added to the serum.
A role for the alternative pathway in mediating the lysis of LTA-E could not be demonstrated when the corresponding autologous sera were treated with EGTA in order to inhibit the classical pathway. There was no evidence that the complement system was being activated in the presence of EGTA even though lysis did not occur, not was there evidence that the EGTA was responsible for removing LTA from the E surface. The EGTAtreated sera were able to support the lysis of rabbit E, demonstrating an intact alternative pathway, at least with respect to rabbit E. Rabbit E are known to be potent activators of the alternative pathway in heterologous sera. However, the lysis of rabbit E in heterologous EGTA-treated sera may not necessarily indicate that the alternative pathway is intact with respect to less potent activating stimuli in autologous systems. Moreover, preferential inhibition ofthe alternative pathway by homologous, but not heterologous, complement has been demonstrated (26) .
The results of the present study suggest that serum deficient in a classical pathway component on a genetic basis may provide a more sensitive means of assessing the role of the autologous alternative pathway in mediating the destruction of LTA-bearing cells.
The current studies did not examine the potential role of antibody in the lysis of LTA-E by autologous complement. We did try a number of different experimental approaches aimed at studying the participation of antibody in the lytic system, but none were successful because of technical limitations. For example, we examined a large number ofgerm-free rats for serum antibody to LTA, but unfortunately they all had significant levels of anti-LTA antibody in their serum. In addition, we also attempted to absorb NRS with unencapsulated pneumococci at 0°C in an attempt to remove anti-LTA antibody but that also diminished the amount of hemolytic complement in the serum.
When rat LTA-E were reinfused into normal autologous donor animals, they underwent rapid intravascular hemolysis. The circulatory survival of LTA-E was greater in the complementdepleted rats than that observed in the normocomplementemic rats, but was nevertheless diminished in comparison with the survival ofcontrol E. While complement-mediated lysis was responsible for the intravascular destruction of the autologous LTA-E in normal rats, animals depleted of functional complement by pretreatment with CoVF did not exhibit any detectable lysis of their reinfused cells. Rather, sequestration of sensitized E in the hepatic tissue of recipient animals accounted for their disappearance in the complement-depleted animals.
The mechanism resonsible for the hepatic sequestration of autologous LTA-E in the CoVF-treated animals is not clear. Such sequestration might have resulted from clearance of antibody-coated cells by the hepatic reticuloendothelial system of the host. In fact, anti-LTA antibody was readily detectable in all the rats tested. Alternatively, the LTA-E might have interacted with the host hepatic tissue on the basis ofaltered surface charge or carbohydrate content. Finally, recent studies have shown that the small amount of C3 which remains after CoVF treatment may be adequate enough to mediate clearance of desialidated E by the reticuloendothelial system even though the levels are not sufficient to support lysis (27) . Thus, the low levels of C3 which remained in the CoVF-treated animals in the current experiments may have been responsible for the clearance of the LTA-E.
The current studies were performed using E as target cells. E were chosen as target cells because they would serve as a convenient general model of the interaction of LTA, host cells, and complement. They are easily obtained from a single animal, conveniently labeled in vitro, and are susceptible to complementmediated lysis. In addition, they can be reinfused into the same animal from which they were obtained, and their in vivo destruction can be determined. It is also possible that LTA fixed to the surface of nucleated cells could act to induce damage by autologous complement. In fact, complement-mediated damage to LTA-sensitized nucleated cells may be more biologically relevant to the situation existing in natural bacterial infections than is complement-mediated damage to LTA-E.
These data demonstrate that complement-mediated host cell destruction can occur both in vitro and in vivo as a result ofthe fixation of LTA to the cell surface. It is possible that this mechanism of host cell damage is operative during the course of natural bacterial infections. Presumably, LTA released locally by gram-positive bacteria would bind to host cells, where it could then interact with antibody and/or autologous complement resulting in host cell destruction. While the presence of anti-LTA antibody would favor damage via activation of the classical pathway, cell damage might also occur in the nonimmune host via activation of the alternative pathway.
